The envisioned flow cytometry test will help to predict patient response to immunotherapies for five cancer indications.

NEW YORK — Genedrive said on Friday that it has received CE marking under the EU's In Vitro Diagnostic Medical Device Regulation (IVDR) for its point-of-care CYP2C19 ID Kit genotyping platform, which ...

The London-based firm will provide its CIZ1B lung cancer test and DEX-G2 gastric cancer test for use in Doctors Hospital in the Cayman Islands.

The companies will develop and commercialize diagnostic tools to help clinicians determine which patients would benefit from precision medicine treatments.

The company's flagship assay uses whole-genome sequencing to identify patients with high-risk multiple myeloma and determine which patients won't respond to therapies.